Medicine guide
Upstaza
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Eladocagene exuparvovec
- Made by
- PTC Therapeutics International Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L amino acid decarboxylase (AADC) deficiency with a severe phenotype (see section 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
Details
| Made by | PTC Therapeutics International Limited |
|---|---|
| Active substance | Eladocagene exuparvovec |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A16AB26 · Digestion, stomach, diabetes and nutrition |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2022-07-18 |
| Last updated by the regulator | 2026-06-10 |
| EMA product number | EMEA/H/C/005352 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).